CO5261510A1 - Inhibidores de aspartil proteasa - Google Patents
Inhibidores de aspartil proteasaInfo
- Publication number
- CO5261510A1 CO5261510A1 CO00008433A CO00008433A CO5261510A1 CO 5261510 A1 CO5261510 A1 CO 5261510A1 CO 00008433 A CO00008433 A CO 00008433A CO 00008433 A CO00008433 A CO 00008433A CO 5261510 A1 CO5261510 A1 CO 5261510A1
- Authority
- CO
- Colombia
- Prior art keywords
- alkyl
- optionally substituted
- alkenyl
- carbon atoms
- independently selected
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 10
- 229920006395 saturated elastomer Polymers 0.000 abstract 9
- 125000001424 substituent group Chemical group 0.000 abstract 9
- 125000000217 alkyl group Chemical group 0.000 abstract 8
- 229910052760 oxygen Inorganic materials 0.000 abstract 8
- 229910052717 sulfur Inorganic materials 0.000 abstract 8
- 125000003342 alkenyl group Chemical group 0.000 abstract 7
- 125000005843 halogen group Chemical group 0.000 abstract 6
- 125000000623 heterocyclic group Chemical group 0.000 abstract 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 6
- 229910052757 nitrogen Inorganic materials 0.000 abstract 6
- 125000005842 heteroatom Chemical group 0.000 abstract 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 3
- -1 -S (O) nQ Chemical group 0.000 abstract 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 3
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 abstract 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 125000006732 (C1-C15) alkyl group Chemical group 0.000 abstract 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 238000006073 displacement reaction Methods 0.000 abstract 1
- 229910052698 phosphorus Inorganic materials 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
- C07C311/38—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
- C07C311/39—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C07C311/42—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
- C07C311/46—Y being a hydrogen or a carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C317/18—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/20—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
- C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Tropical Medicine & Parasitology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Un compuesto de fórmula I:<EMI FILE="00008433_1" ID="1" IMF=JPEG >o una sal farmacéuticamente aceptable del mismo, en donde:E' es -CO- o -SO2-;A se selecciona a partir de H; Ht; R1-Ht; -R1-C1-C6 alquilo, el cual esta sustituido opcionalmente con 1 o más grupos independientemente seleccionados de hidroxi , alcoxi con 1 a 4 átomos de carbono, Ht, -O-Ht, -NR2-CO-N(R2)2, -SO2-R2 o -CO-N(R2)2, -R1 alquenilo con 2 a 6 átomos de carbono, el cual es sustituido opcionalmente con 1 o mas grupos independientemente seleccionados de hidroxi, alcoxi con 1 a 4 átomos de carbono, Ht, -O-Ht, -NR2-CO-N(R2)2 o -CO-N(R2)2; o R7; en donde:Cada R1 es independientemente seleccionado a partir de -C(O)-, -S(O)2-, -C(O)-C(O)-, -O-C(O)-, -O-S(O)2, -NR2-S(O)2-, -NR2-C(O)- o -NR2-C(O)-C(O)-;Cada Ht seleccionado independientemente de cicloalquilo con 3 a 7 átomos de carbono, cicloalquenilo con 5 a 7 átomos de carbono; arilo con 6 a 14 átomos de carbono; o un heterociclo no saturado o saturado con 5 a 7 miembros, que contiene 1 o mas heteroátomos seleccionados entre N, O, o S; en donde dicho arilo o dicho heterociclo esta opcionalmente fundido a Q; y en donde cualquier miembro de dicho Ht es opcionalmente sustituido con 1 o mas sustituyentes independientemente seleccionados de oxo, -OR2, SR2, -R2, -N(R2)(R2), -R2-OH, -CN, -CO2R2, -C(O)-N(R2)2, -S(O)2-N(R2)2, -N(R2)-C(O)-R2, -N(R2)-C(O)O-R2, -C(O)-R2, -S(O)n-R2, -OCF3, -S(O)n-Q, metilenedioxi, -N(R2)-S(O)2(R2), halo, -CF3, -NO2, Q, OQ, -OR7, -SR7, -R7, -N(R2)(R7) o -N(R7)2;Cada Q se selecciona independientemente a partir de un sistema de anillo carboxílico parcialmente saturado o no saturado con 3 a 7 miembros saturados; o un anillo heterocíclico parcialmente saturado o no saturado con 5 a - 2 -7 miembros saturados que contiene uno o más heteroátomos seleccionados a partir de O, N, o S, en donde Q es sustituido opcionalmente con 1 o más grupos que seleccionan de oxo, -OR2, -R2, -SO2R2, -SO2-N(R2)2, -N(R2)2, -N(R2)-C(O)-R2, -R2-OH, -CN, -CO2R2, -C(O)-N(R2)2, halo o CF3;Cada R2 se selecciona independientemente de H, o alquilo con 1 a 4 átomos de carbono en donde dicho alquilo, cuando no es un sustituyente de Q, es sustituido opcionalmente con Q o -OR3; en donde cuando dicho R2 es una porción substituida -OR3, dicho R3 en -OR3 puede no ser -OR2 substituido;B, cuando está presente, es -N(R2)-C(R3)2-C(O)-;Cada x es independientemente 0 o 1;Cada R3 es seleccionado independientemente de H, Ht, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-6 o cicloalquenilo C5-6; en donde cualquier miembro de dicho R3, excepto H, es sustituido opcionalmente con uno o más sustituyentes seleccionados a partir de -OR2, -C(O)-NH-R2, -S(O)n-N(R2)(R2), -N(R2)2, -N(R2)-C(O)-O(R2), -N(R2)-C(O)-N(R2), -N(R2)-C(O)-(R2), Ht, -CN, -SR2, -CO2R2, o NR2-C(O)-R2;Cada n es independientemente 1 o 2;G, cuando está presente, se selecciona a partir de H, R7 o alquilo C1-4, o, cuando G es alquilo con 1 a 4 átomos de carbono, G y R7 están opcionalmente ligados uno al otro sea directamente o a través de un ligador con 1 a 3 átomos de carbono para formar un anillo heterocíclico; oCuando G no está presente, el nitrógeno al cual G está ligado se liga directamente al grupo R7 en -OR7 con el desplazamiento concomitante de un grupo -ZM desde R7;D es seleccionado a partir de Q, alquilo C1-6 opcionalmente sustituido con 1 o más grupos seleccionados a partir de cicloalquilo C3-6, -OR2, -S-Ht, -R3, -O-Q o Q; alquenilo con 2 a 4 átomos de carbono sustituido opcionalmente con 1 o más grupos seleccionados a partir de -OR2, -S-Ht, -R3, -O-Q o Q; cicloalquilo C3-6 opcionalmente sustituido con o fundido con Q; o cicloalquenilo C5-6 opcionalmente sustituido con o fundido a Q;D' es seleccionado de alquilo C1-C15, alquenilo C2-C15 o alquinilo C2-C15, cada uno de los cuales contiene uno o más sustituyentes seleccionados de oxo, halo, -CF3, -OCF3, -NO2, azido, -SH, -SR3, - N(R3)-N(R3)2, -O-N(R3)2, -(R3)N-O-(R3), -N(R3)2, -CN, -CO2R, -C(O)-N(R3)2 -S(O)n-N(R3)2, -N(R3)-C(O)-R3, -N(R3)-C(O)-N(R3)2, -N(R3)-C(O)-S(R3)2, -C(O)-R3, -S(O)n-R3, -N(R3)-S(O)n(R3), -N(R3)-S(O)n-N(R3)2, -S-NR3-C(O)R3, -C(S)N(R3)2, - C(S)R3, -NR3-C(O)OR3, -O-C(O)OR3, -O-C(O)N(R3)2, -NR3 C(S)R3, =N-OH, =N-OR3, =N-N(R3)2, =NR3, =NNR3C(O)N(R3)2, =NNR3C(O)OR3, =NNR3S(O)n-N(R3)2, -NR3-C(S)OR3, -NR3-C(S)N(R3)2, -NR3-C[=N(R3)]-N(R3)2, -N(R3)-C[=N-NO2]-N(R3)2, -N(R3)-C[=N-NO2]-OR3, -N(R3)-C[=N-CN]-OR3, N(R3)-C[=N-CN]-(R3)2, -OC(O)R3, -OC(S)R3, -OC(O)N(R3)2, -C(O)N(R3)-N(R3)2, -O-C(O)N(R3)-N(R3)2, O-C(O)N(OR3)(R3), N(R3)-N(R3)C(O)R3, N(R3)-OC(O)R3, N(R3)-OC(O)R3, N(R3)-OC(O)R3, -OC(S)N(R3)2, -OC(S)N(R3)(R3), o PO3-R3; con la condición de que cuando R7 es H, E´ es -SO2, G es H o alquilo, y cuando B esta presente o cuando B no está presente y R1 es -C(O)-, D´ puede no ser alquilo sustituido de 1 a 15 carbonos con un sustituyente seleccionado de -N(R3)2, -SR3 o -S(O)n-R3, o sustituido con dos -N(R3)2 sustituyentes; E se selecciona a partir de Ht; O-Ht; Ht-Ht; Ht fundido con Ht; -O-R3; -N(R2)(R3); alquilo C1-C6 opcionalmente sustituido con uno o más grupos seleccionados a partir de R4 o Ht; alquenilo C2-C6 opcionalmente substituido con 1 o más grupos seleccionados a partir de R4 o Ht; carbociclo saturado con C3-C6 opcionalmente sustituido con o más grupos seleccionados a partir de R4 o Ht; o carbociclo insaturado con C5-C6 opcionalmente sustituido con uno o más grupos seleccionados de R4 o Ht; Cada R4 es seleccionado independientemente a partir de -OR2, -OR3, -SR2, -SOR2, -SO2R2, CO2R2, -C(O)-NHR2, -C(O)-N(R2)2, -C(O)-NR2(OR2), -S(O)2-NHR2, halo, -NR2-C(O)-R2, -N(R2)2 O -CN;Cada R7 es seleccionado independientemente a partir de hidrógeno, <EMI FILE="00008433_2" ID="2" IMF=JPEG > En donde cada M es seleccionado independientemente a partir de H, Li, Na, K, Mg, Ca, Ba, -N(R2)4, alquilo C1-C12, - 3 - alquenilo C2-C12, o -R6; en donde 1 a 4 de los radicales -CH2 del grupo alquilo o alquenilo, diferentes del -CH2 que esta ligado al Z, es reemplazado opcionalmente por un grupo heteroátomo seleccionado a partir de O, S(O), S(O)2, o N(R2); y en donde cualquier hidrógeno en dicho alquilo, alquenilo o R6 es reemplazado opcionalmente con un sustituyente seleccionado a partir de oxo, -OR2, -R2, N(R2)2, N(R2)3, R2OH, -CN, -CO2R2, -C(O)-N(R2)2, S(O)2-N(R2)2, N(R2)-C(O)-R2, C(O)R2, -S(O)n-R2, OCF3, -S(O)n-R6, -N(R2)-S(O)2-(R2), halo, -CF3, o -NO2;M' es H, alquilo C1-C12, alquenilo C2-C12, o R6; en donde los radicales 1 a 4 de -CH2 del grupo alquilo o alquenilo se reemplazan opcionalmente por un grupo de heteroátomos seleccionados a partir de O, S, S(O), S(O)2, o N(R2); y en donde cualquier hidrógeno en dicho alquilo, alquenilo, o R6 es reemplazado opcionalmente con un sustituyente seleccionado a partir de oxo, -OR2, -R2, -N(R2)2, N(R2)3, -R2OH, -CN, -CO2R2, -C(O)-N(R2)2, -S(O)2-N(R2)2, -N(R2)-C(O)-R2, C(O)R2, -S(O)n-R2, OCF3, -S(O)n-R6, -N(R2)-S(O)2-(R2), halo, -CF3, o -NO2;Z es O, S, N(R2)2, o, cuando M no esta presente, H.Y es P o S;X es O o S;R9 es C(R2)2, O o N(R2); en donde cuando Y es S, Z no es S;R6 es un sistema de anillo heterocíclico o carbocíclico saturado o no saturado parcialmente con 5 a 6 miembros saturados, o un sistema de anillo bicíclico parcialmente saturado o no saturado con 8 a 10 miembros saturados; en donde cada uno de dichos sistemas de anillos heterocíclicos contiene uno o más heteroátomos seleccionados a partir de O, N, S, S(O)n o N(R2); y en donde cualquiera de los sistemas de dichos anillos contiene opcionalmente 1 a 4 sustituyentes independientemente seleccionados a partir de OH, alquilo C1-C4, alquilo -O-C1-C4- o alquilo -O-C(O)-C1-C4.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12004799P | 1999-02-12 | 1999-02-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO5261510A1 true CO5261510A1 (es) | 2003-03-31 |
Family
ID=37874715
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO00008433A CO5261510A1 (es) | 1999-02-12 | 2000-02-09 | Inhibidores de aspartil proteasa |
Country Status (4)
Country | Link |
---|---|
US (4) | US6319946B1 (es) |
CO (1) | CO5261510A1 (es) |
TN (1) | TNSN00027A1 (es) |
TW (1) | TWI260322B (es) |
Families Citing this family (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040122000A1 (en) * | 1981-01-07 | 2004-06-24 | Vertex Pharmaceuticals Incorporated. | Inhibitors of aspartyl protease |
US6436989B1 (en) | 1997-12-24 | 2002-08-20 | Vertex Pharmaceuticals, Incorporated | Prodrugs of aspartyl protease inhibitors |
TWI260322B (en) * | 1999-02-12 | 2006-08-21 | Vertex Pharma | Inhibitors of aspartyl protease |
TWI286476B (en) * | 2001-12-12 | 2007-09-11 | Tibotec Pharm Ltd | Combination of cytochrome P450 dependent protease inhibitors |
WO2003057173A2 (en) * | 2002-01-07 | 2003-07-17 | Sequoia Pharmaceuticals | Broad spectrum inhibitors |
US7157489B2 (en) * | 2002-03-12 | 2007-01-02 | The Board Of Trustees Of The University Of Illinois | HIV protease inhibitors |
CN1313472C (zh) * | 2002-04-26 | 2007-05-02 | 吉里德科学公司 | Hiv蛋白酶抑制剂化合物的膦酸酯类似物的细胞蓄积及这类化合物 |
US20050261237A1 (en) * | 2003-04-25 | 2005-11-24 | Boojamra Constantine G | Nucleoside phosphonate analogs |
WO2005002626A2 (en) * | 2003-04-25 | 2005-01-13 | Gilead Sciences, Inc. | Therapeutic phosphonate compounds |
EA014685B1 (ru) | 2003-04-25 | 2010-12-30 | Джилид Сайэнс, Инк. | Фосфонатсодержащие антивирусные соединения (варианты) и фармацевтическая композиция на их основе |
AU2004233897A1 (en) * | 2003-04-25 | 2004-11-11 | Gilead Sciences, Inc. | Kinase inhibitor phosphonate conjugates |
US7470724B2 (en) * | 2003-04-25 | 2008-12-30 | Gilead Sciences, Inc. | Phosphonate compounds having immuno-modulatory activity |
CN101410120A (zh) * | 2003-04-25 | 2009-04-15 | 吉里德科学公司 | 抗炎的膦酸酯化合物 |
US7452901B2 (en) * | 2003-04-25 | 2008-11-18 | Gilead Sciences, Inc. | Anti-cancer phosphonate analogs |
US20090247488A1 (en) * | 2003-04-25 | 2009-10-01 | Carina Cannizzaro | Anti-inflammatory phosphonate compounds |
US7427636B2 (en) * | 2003-04-25 | 2008-09-23 | Gilead Sciences, Inc. | Inosine monophosphate dehydrogenase inhibitory phosphonate compounds |
WO2004096285A2 (en) * | 2003-04-25 | 2004-11-11 | Gilead Sciences, Inc. | Anti-infective phosphonate conjugates |
US7432261B2 (en) * | 2003-04-25 | 2008-10-07 | Gilead Sciences, Inc. | Anti-inflammatory phosphonate compounds |
US7407965B2 (en) * | 2003-04-25 | 2008-08-05 | Gilead Sciences, Inc. | Phosphonate analogs for treating metabolic diseases |
WO2005000249A2 (en) * | 2003-06-27 | 2005-01-06 | Smithkline Beecham Corporation | Preparation of chemical compounds |
US7273715B2 (en) * | 2003-10-24 | 2007-09-25 | Gilead Sciences, Inc. | Methods and compositions for identifying therapeutic compounds with GS-9005 ester hydrolase A |
WO2005044279A1 (en) * | 2003-10-24 | 2005-05-19 | Gilead Sciences, Inc. | Purine nucleoside phosphonate conjugates |
US7432273B2 (en) * | 2003-10-24 | 2008-10-07 | Gilead Sciences, Inc. | Phosphonate analogs of antimetabolites |
US20050153990A1 (en) * | 2003-12-22 | 2005-07-14 | Watkins William J. | Phosphonate substituted kinase inhibitors |
BRPI0417988A (pt) * | 2003-12-22 | 2007-04-27 | Gilead Sciences Inc | análogos de fosfonato antivirais |
BRPI0418031A (pt) * | 2003-12-22 | 2007-04-17 | Gilead Sciences Inc | inibidores de quinase fosfonato-substituìdos |
JP2007528423A (ja) * | 2004-03-11 | 2007-10-11 | セコイア、ファーマシューティカルズ、インコーポレイテッド | 耐性防止レトロウイルスプロテアーゼ阻害薬 |
JP5073480B2 (ja) | 2004-05-07 | 2012-11-14 | セコイア、ファーマシューティカルズ、インコーポレイテッド | 耐性防止レトロウイルスプロテアーゼ阻害薬 |
ATE505196T1 (de) | 2004-07-27 | 2011-04-15 | Gilead Sciences Inc | Nukleosid phosphonat konjugate als anti hiv mittel |
EP2139883A4 (en) * | 2007-03-23 | 2011-06-22 | Univ Massachusetts | INHIBITORS OF HIV-1 PROTEASE |
US8569364B2 (en) | 2007-11-28 | 2013-10-29 | Sequoia Pharmaceuticals, Inc. | 5-substituted benzofurans as inhibitors of cytochrome P450 2D6 |
CA2716348C (en) | 2008-02-21 | 2017-04-04 | Sequoia Pharmaceuticals, Inc. | Diamide inhibitors of cytochrome p450 |
US20100093667A1 (en) | 2008-07-08 | 2010-04-15 | Gilead Sciences, Inc. | Salts of hiv inhibitor compounds |
EP2723758B1 (en) | 2011-06-21 | 2018-06-20 | Alnylam Pharmaceuticals, Inc. | Angiopoietin-like 3 (angptl3) irna compostions and methods of use thereof |
EP2723390B1 (en) | 2011-06-23 | 2017-12-27 | Alnylam Pharmaceuticals, Inc. | Serpina1 sirnas: compositions of matter and methods of treatment |
EP2726108B1 (en) | 2011-06-29 | 2018-01-10 | The Trustees of Columbia University in the City of New York | Inhibitor of neuronal connectivity linked to schizophrenia susceptibility and cognitive dysfunction |
US9127274B2 (en) | 2012-04-26 | 2015-09-08 | Alnylam Pharmaceuticals, Inc. | Serpinc1 iRNA compositions and methods of use thereof |
WO2014075093A1 (en) * | 2012-11-09 | 2014-05-15 | The Trustees Of Columbia University In The City Of New York | Inhibitors of central nervous system vasoactive inhibitory peptide receptor 2 |
JP6574383B2 (ja) | 2012-12-05 | 2019-09-11 | アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. | PCSK9iRNA組成物及びその使用方法 |
PL2970974T3 (pl) | 2013-03-14 | 2018-01-31 | Alnylam Pharmaceuticals Inc | Kompozycje komponentu C5 dopełniacza iRNA i sposoby ich zastosowania |
AP2015008862A0 (en) | 2013-05-22 | 2015-11-30 | Alnylam Pharmaceuticals Inc | Tmprss6 irna compositions and methods of use thereof |
MY176712A (en) | 2013-05-22 | 2020-08-19 | Alnylam Pharmaceuticals Inc | Serpina1 irna compositions and methods of use thereof |
AU2014362262B2 (en) | 2013-12-12 | 2021-05-13 | Alnylam Pharmaceuticals, Inc. | Complement component iRNA compositions and methods of use thereof |
KR102389968B1 (ko) | 2014-02-11 | 2022-04-25 | 알닐람 파마슈티칼스 인코포레이티드 | 케토헥소키나제(KHK) iRNA 조성물 및 그의 사용 방법 |
TW201607559A (zh) | 2014-05-12 | 2016-03-01 | 阿尼拉製藥公司 | 治療serpinc1相關疾患之方法和組成物 |
WO2015179724A1 (en) | 2014-05-22 | 2015-11-26 | Alnylam Pharmaceuticals, Inc. | Angiotensinogen (agt) irna compositions and methods of use thereof |
WO2016039403A1 (ja) * | 2014-09-11 | 2016-03-17 | 塩野義製薬株式会社 | 持続性hivプロテアーゼ阻害剤 |
WO2016040589A1 (en) | 2014-09-12 | 2016-03-17 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting complement component c5 and methods of use thereof |
EP3207138B1 (en) | 2014-10-17 | 2020-07-15 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting aminolevulinic acid synthase-1 (alas1) and uses thereof |
WO2016069694A2 (en) | 2014-10-30 | 2016-05-06 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting serpinc1 (at3) and methods of use thereof |
CN113846101A (zh) | 2014-11-17 | 2021-12-28 | 阿尔尼拉姆医药品有限公司 | 载脂蛋白C3(APOC3)iRNA组合物及其使用方法 |
WO2016130806A2 (en) | 2015-02-13 | 2016-08-18 | Alnylam Pharmaceuticals, Inc. | Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof |
CA2982450A1 (en) | 2015-04-13 | 2016-10-20 | Alnylam Pharmaceuticals, Inc. | Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof |
AU2016257996A1 (en) | 2015-05-06 | 2017-10-26 | Alnylam Pharmaceuticals, Inc. | Factor XII (Hageman Factor) (F12), Kallikrein B, Plasma (Fletcher Factor) 1 (KLKB1), and Kininogen 1 (KNG1) iRNA compositions and methods of use thereof |
EP3307316A1 (en) | 2015-06-12 | 2018-04-18 | Alnylam Pharmaceuticals, Inc. | Complement component c5 irna compositions and methods of use thereof |
WO2016205323A1 (en) | 2015-06-18 | 2016-12-22 | Alnylam Pharmaceuticals, Inc. | Polynucleotde agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof |
EP3350328A1 (en) | 2015-09-14 | 2018-07-25 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting patatin-like phospholipase domain containing 3 (pnpla3) and methods of use thereof |
KR20180095843A (ko) | 2015-12-07 | 2018-08-28 | 젠자임 코포레이션 | Serpinc1-연관 장애의 치료를 위한 방법 및 조성물 |
EP3387129A1 (en) | 2015-12-10 | 2018-10-17 | Alnylam Pharmaceuticals, Inc. | STEROL REGULATORY ELEMENT BINDING PROTEIN (SREBP) CHAPERONE (SCAP) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
EP3469083A1 (en) | 2016-06-10 | 2019-04-17 | Alnylam Pharmaceuticals, Inc. | COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) |
TWI788312B (zh) | 2016-11-23 | 2023-01-01 | 美商阿尼拉製藥公司 | 絲胺酸蛋白酶抑制因子A1 iRNA組成物及其使用方法 |
WO2018112320A1 (en) | 2016-12-16 | 2018-06-21 | Alnylam Pharmaceuticals, Inc. | Methods for treating or preventing ttr-associated diseases using transthyretin (ttr) irna compositions |
CA3070319A1 (en) | 2017-07-21 | 2019-01-24 | Viiv Healthcare Company | Regimens for treating hiv infections and aids |
SI3661937T1 (sl) | 2017-08-01 | 2021-11-30 | Gilead Sciences, Inc. | Kristalinične oblike etil((S)-((((2R,5R)-5-(6-amino-9H-purin-9-IL)-4- fluoro-2,5-dihidrofuran-2-IL)oksi)metil)(fenoksi)fosforil)-L-alaninata (GS-9131) za zdravljenje virusnih okužb |
AU2018360697A1 (en) | 2017-11-01 | 2020-05-14 | Alnylam Pharmaceuticals, Inc. | Complement component C3 iRNA compositions and methods of use thereof |
CN112673103A (zh) | 2018-08-13 | 2021-04-16 | 阿尔尼拉姆医药品有限公司 | 乙型肝炎病毒(HBV)dsRNA剂组合物及其使用方法 |
SG11202107669WA (en) | 2019-01-16 | 2021-08-30 | Genzyme Corp | Serpinc1 irna compositions and methods of use thereof |
WO2021154941A1 (en) | 2020-01-31 | 2021-08-05 | Alnylam Pharmaceuticals, Inc. | Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als) |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4604402A (en) | 1984-03-30 | 1986-08-05 | E. R. Squibb & Sons, Inc. | Hydroxy substituted ureido amino and imino acids |
US4629724A (en) | 1984-12-03 | 1986-12-16 | E. R. Squibb & Sons, Inc. | Amino acid ester and amide renin inhibitors |
DK0656887T3 (da) | 1992-08-25 | 1999-07-05 | Searle & Co | Hydroxyethylaminosulfonamider til anvendelse som inhibitorer af retrovirale proteaser |
IS2334B (is) | 1992-09-08 | 2008-02-15 | Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) | Aspartyl próteasi hemjari af nýjum flokki súlfonamíða |
US5723490A (en) | 1992-09-08 | 1998-03-03 | Vertex Pharmaceuticals Incorporated | THF-containing sulfonamide inhibitors of aspartyl protease |
TW372972B (en) | 1992-10-23 | 1999-11-01 | Novartis Ag | Antiretroviral acyl compounds |
ES2134924T3 (es) | 1992-10-30 | 1999-10-16 | Searle & Co | Acidos sulfonilalcanoilamino-hidroxietilamino-sulfamicos utiles como inhibidores de proteasas retrovirales. |
US5484926A (en) | 1993-10-07 | 1996-01-16 | Agouron Pharmaceuticals, Inc. | HIV protease inhibitors |
AU7669794A (en) | 1993-08-24 | 1995-03-21 | G.D. Searle & Co. | Hydroxyethylamino sulphonamides useful as retroviral protease inhibitors |
IL110898A0 (en) | 1993-09-10 | 1994-11-28 | Narhex Australia Pty Ltd | Polar-substituted hydrocarbons |
IL111584A0 (en) | 1993-11-18 | 1995-01-24 | Merck & Co Inc | Prodrugs of an inhibitor of hiv protease and pharmaceutical compositions containing them |
US5527829A (en) | 1994-05-23 | 1996-06-18 | Agouron Pharmaceuticals, Inc. | HIV protease inhibitors |
JP4014220B2 (ja) * | 1995-01-20 | 2007-11-28 | ジー.ディー.サール アンド カンパニー | ビス−スルホンアミドヒドロキシエチルアミノ レトロ ウイルスプロテアーゼインヒビター |
US5691372A (en) * | 1995-04-19 | 1997-11-25 | Vertex Pharmaceuticals Incorporated | Oxygenated-Heterocycle containing sulfonamide inhibitors of aspartyl protease |
TWI260322B (en) * | 1999-02-12 | 2006-08-21 | Vertex Pharma | Inhibitors of aspartyl protease |
-
2000
- 2000-02-09 TW TW089102108A patent/TWI260322B/zh not_active IP Right Cessation
- 2000-02-09 US US09/500,781 patent/US6319946B1/en not_active Expired - Lifetime
- 2000-02-09 CO CO00008433A patent/CO5261510A1/es not_active Application Discontinuation
- 2000-02-09 TN TNTNSN00027A patent/TNSN00027A1/fr unknown
-
2001
- 2001-08-09 US US09/927,271 patent/US6617350B2/en not_active Expired - Fee Related
-
2003
- 2003-07-02 US US10/613,650 patent/US7442718B2/en not_active Expired - Fee Related
-
2008
- 2008-07-02 US US12/217,517 patent/US7919523B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
US20040127488A1 (en) | 2004-07-01 |
TWI260322B (en) | 2006-08-21 |
US7442718B2 (en) | 2008-10-28 |
TNSN00027A1 (fr) | 2005-11-10 |
US6319946B1 (en) | 2001-11-20 |
US20090042973A1 (en) | 2009-02-12 |
US7919523B2 (en) | 2011-04-05 |
US6617350B2 (en) | 2003-09-09 |
US20020198388A1 (en) | 2002-12-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO5261510A1 (es) | Inhibidores de aspartil proteasa | |
CO5160337A1 (es) | Inhibidores de aspartilo proteasa proteasa | |
CO4990992A1 (es) | Profarmacos de compuestos de sulfonamida como inhibidores de aspartil proteasa | |
AR042635A1 (es) | Imidazoquinolinas arilsustituidas y composiciones farmaceuticas que las contienen | |
CO5721006A2 (es) | Derivados de pirazolo-quinazolina, proceso para su preparacion y su uso como inhibidores de quinasa | |
AR117139A1 (es) | Derivados de piridooxazinona como inhibidores de monoacilglicerol ligasa (magl) | |
AR127309A2 (es) | Derivados de piridazinona | |
AR045529A1 (es) | Imidazoquinolinas sustituidas con grupos ariloxi o arilalquilenoxi | |
AR076486A1 (es) | Inhibidores de fosfoinositida 3 kinasa y composiciones farmaceuticas que los contienen. | |
AR107032A1 (es) | Inhibidores bicíclicos de pad4 | |
CA2217745A1 (en) | Oxygenated-heterocycle containing sulfonamide inhibitors of aspartyl protease | |
AR088828A1 (es) | DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3 | |
PE20241063A1 (es) | Composiciones y metodos para la inhibicion de ras | |
PE20212070A1 (es) | Moduladores de trex1 | |
AR083953A1 (es) | Compuestos para tratar enfermedades neurodegenerativas | |
AR059621A1 (es) | Acidos 4- fenil- tiazol-5- carboxilicos y amidas de acidos 4- fenil- tiazol5 carboxilicos como inhibidores de la plk1 | |
AR058180A1 (es) | Indeno derivados, su preparacion y su uso como medicamentos | |
CO2020001326A2 (es) | Nuevos compuestos heterocíclicos como inhibidores de cdk8/19 | |
AR059520A1 (es) | Derivados de ariltienopirimidinonas azaciclil sustituidas,procedimiento para su preparacion,medicamentos que las contienen y usos terapeuticos como antagonistas de receptores mch1r. | |
AR107030A1 (es) | Inhibidores aza-bencimidazol de pad4 | |
AR126053A1 (es) | Derivados de triazina | |
PE20220704A1 (es) | Derivados de 3,6-diamino-piridazin-3-ilo, composiciones farmaceuticas que los contienen y sus usos como agentes proapoptoticos | |
AR116905A1 (es) | Derivados de ácido pirrolidino-2-carboxílico para tratar el dolor y afecciones relacionadas con el dolor | |
AR122986A1 (es) | Derivados de piridazina como inhibidores de alk5 y/o alk4 | |
PE20230110A1 (es) | Procesos para la preparacion de un inhibidor de cinasa |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Application withdrawn |